FDA gives nod to chemoimmunotherapy for patients suffering from DLBCL
Category: #health  By Mateen Dalal  Date: 2019-06-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA gives nod to chemoimmunotherapy for patients suffering from DLBCL

Polivy is an innovative antibody-drug conjugate developed with an intention of targeting specific cells

Reports confirm that the US Food and Drug Administration has awarded accelerated approval to Polivy (polatuzumab vedotin-piiq), for use in combination with a rituximab product and chemotherapy bendamustine (BR combination). The drug is expected to treat patients with diffuse large B-cell lymphoma (DLBCL) that has either progressed or returned after two therapies taken previously.

Director of the Oncology Centre of Excellence at FDA and acting director of FDA’s Office of Hematology and Oncology Products, Richard Pazdur commented that as a growing form of targeted immunotherapies made for cancer, antibody-drug conjugates are nothing like traditional therapy.

Antibody-drug conjugates, like Polivy, are developed with the intension of targeting specific cells. Supposedly, there have been several treatments for the disease that have not produced any results, and the approval is expected to help provide these patients with an alternative option, Pazdur informed.

DLBCL affects over 18,000 people annually and about 30-40% of patients often suffer from relapses. This cancer grows quickly and has the potential to affect liver, marrow, spleen and other organs.

Reportedly, a chemotherapy drug is attached with Polivy, an antibody which is created specifically to bind itself to a certain protein called CD79b mainly found in B cells. It then gradually releases the chemotherapy drugs into the cells.

Citing reliable sources, 80 patients with refracted or relapsed DLBCL were studied to evaluate the drug’s success. The patients were randomized while they received Polivy with BR or BR alone. The treatment ended with 40% complete response rate with Polivy and BR, in comparison to 18% with BR alone. 25 patients secured a complete or a partial response to the drug tested out, of which 16 had a Duration of Response of at least 6 months and 12 of them had a Duration Of Response of 12 months.

Polivy had been given the Orphan Drug designation by FDA, a designation which provides incentives to encourage and assist in developments of rare diseases.

Source Credit- https://www.fda.gov/news-events/press-announcements/fda-approves-first-chemoimmunotherapy-regimen-patients-relapsed-or-refractory-diffuse-large-b-cell

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
By Mateen Dalal

Mercedes-AMG Petronas F1 Team, and Advanced Micro Devices (AMD), a renowned semiconductor developer, have reportedly announced a new multi-year partnership agreement that has combined the two firms’ passion of for high performance, beginning fr...

Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
By Mateen Dalal

The biopharmaceutical giant has also received a USD 10 million development milestone payment from Merck & CO. for the initiation of the trial A clinical-stage biopharmaceutical company, Aduro Biotech, Inc. recently announced to have ba...

TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
By Mateen Dalal

TherapeuticsMD, Inc., an inventive pharmaceutical company that focuses on women healthcare, has recently announced that it has presented a New Drug Application (NDA) pre-approval efficacy supplement to the U.S. FDA (Food and Drug Administration) for ...